By NorthPeptide Research Team · April 9, 2026
TL;DR: Ipamorelin and GHRP-6 are both growth hormone secretagogues — they tell your pituitary to release GH. But ipamorelin is highly selective (GH only, no cortisol spike, no hunger surge), while GHRP-6 is more potent but brings ghrelin-driven appetite stimulation and a cortisol bump. If your research needs clean GH pulses without metabolic noise, ipamorelin is the cleaner tool. If appetite stimulation is part of the protocol, GHRP-6 has a role.
⚠️ Research Use Only: All content on this page is for educational and informational purposes. These compounds are for laboratory and research use only. Not for human consumption. NorthPeptide does not provide medical advice.
What Are Growth Hormone Secretagogues?
Growth hormone secretagogues (GHS) are compounds that stimulate the pituitary gland to produce and release growth hormone (GH). They work by binding to the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor.
Two of the most widely studied GHS peptides in research are ipamorelin and GHRP-6. Both trigger GH pulses. Both are hexapeptides (well — ipamorelin is a pentapeptide, GHRP-6 is a hexapeptide). Both have substantial published literature behind them. But they are not interchangeable.
Understanding the differences matters because the choice between them can change the entire profile of a research protocol — from the magnitude of the GH response to the downstream hormonal noise that comes with it.
Ipamorelin: The Selective GH Pulse
Ipamorelin (Ala-His-D-2-Nal-D-Phe-Lys-NH2) was developed in the late 1990s specifically to address the off-target hormonal effects of earlier GHS compounds. It binds the GHS-R with high affinity but shows remarkable selectivity: it stimulates GH release without meaningfully elevating cortisol, prolactin, or adrenocorticotropic hormone (ACTH).
This selectivity is the defining characteristic of ipamorelin. In an early key study by Raun et al. (1998), ipamorelin stimulated GH release in rats at levels comparable to GHRP-6, but without the cortisol and ACTH elevations that GHRP-6 produced. This was a significant finding — it showed that separating GH release from the stress hormone cascade was possible.
Ipamorelin GH Pulse Profile
Onset: GH peaks approximately 15–30 minutes post-administration Duration: Pulse is brief and returns to baseline within 2–3 hours, mimicking natural pulsatile GH secretion Magnitude: Moderate — meaningful GH elevation without supraphysiological spikes Cortisol effect: Minimal to none at typical research doses Prolactin effect: None observed in controlled research Appetite effect: Minimal — ipamorelin has weak ghrelin-mimetic activity at GI-level receptors
Ipamorelin is frequently studied in combination with CJC-1295 or sermorelin (GHRH analogues) because the combination approach — one compound releasing stored GH, the other amplifying the signal — produces larger, more sustained GH elevations than either alone.
GHRP-6: The Potent but Noisy Secretagogue
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is one of the original synthetic GHS peptides. It was among the first compounds to demonstrate that GH release could be triggered through a receptor pathway independent of GHRH, which was a breakthrough in understanding pituitary regulation.
GHRP-6 binds the GHS-R with high affinity and produces robust GH pulses — in some studies, larger peak GH elevations than ipamorelin at equivalent molar doses. But it also has significant off-target activity.
GHRP-6 GH Pulse Profile
Onset: GH peaks approximately 15–30 minutes post-administration Duration: Similar pulse kinetics to ipamorelin — returns to baseline within 2–3 hours Magnitude: High — GHRP-6 tends to produce larger peak GH responses than ipamorelin at the same dose Cortisol effect: Measurable elevation — studies show ACTH and cortisol rise alongside GH Prolactin effect: Mild elevation documented Appetite effect: Strong — GHRP-6 has potent ghrelin-mimetic activity, triggering significant hunger in research subjects
The appetite effect is mechanistically important: GHRP-6 activates the same GHS-R1a receptor in the hypothalamus and gastric cells that ghrelin activates. Ghrelin's primary natural role is hunger signaling. So GHRP-6 does not just trigger GH release — it activates a full ghrelin-pathway response, including appetite stimulation and gastric motility changes.
Head-to-Head Comparison
Parameter Ipamorelin GHRP-6 Structure Pentapeptide Hexapeptide Receptor GHS-R1a (selective) GHS-R1a (broad ghrelin-mimetic) GH Pulse Magnitude Moderate High Cortisol Elevation None / minimal Measurable increase Prolactin Elevation None Mild Appetite Effect Minimal Strong (ghrelin pathway) ACTH Effect None Elevated Research Selectivity High — GH-specific studies Broader — GH + appetite + GI Combination Use Commonly paired with CJC-1295 Can pair with GHRH analogues Published Human Trials Yes (limited — mostly preclinical) Yes (more extensive preclinical)
Which Research Goal Points to Which Compound?
Use Ipamorelin When:
The research question involves isolated GH secretion without confounding cortisol or appetite variables The protocol involves aging or body composition research where cortisol elevation would be a confounder The design calls for long-duration dosing — ipamorelin's clean side-effect profile makes sustained protocols more manageable The research is studying GH pulse timing and amplitude — ipamorelin's predictable, clean pulses make it the more controlled research tool The protocol involves combination with GHRH analogues (CJC-1295, sermorelin) — ipamorelin + CJC-1295 is one of the best-characterized two-peptide GH secretagogue combinations in the literature
Use GHRP-6 When:
The research goal includes appetite or food intake modulation as a variable — GHRP-6's strong ghrelin-mimetic activity is a feature, not a bug, in this context The protocol needs maximum GH release magnitude and hormonal noise is acceptable or controlled for The study involves ghrelin pathway biology — GHRP-6 is a useful tool for understanding the GHS-R/ghrelin axis beyond GH secretion The research is comparing selective vs non-selective GHS compounds — GHRP-6 serves well as the non-selective comparator
Mechanism: Why Do They Behave Differently?
Both ipamorelin and GHRP-6 bind GHS-R1a, but they have different binding conformations and downstream signaling profiles. Ipamorelin appears to have a more restricted signaling footprint — activating the GH-release pathway with minimal engagement of other GHS-R1a-mediated cascades (cortisol, ACTH, ghrelin-like GI signaling).
GHRP-6, structurally closer to the endogenous ghrelin peptide, engages the receptor in a way that more closely mimics the full ghrelin response. Ghrelin evolved not just to trigger GH release but to signal caloric need to the brain — so a more faithful ghrelin mimic will activate more of those pathways.
This is sometimes called "functional selectivity" or "biased agonism" at the GHS-R — the idea that different ligands binding the same receptor can produce different downstream signaling profiles. Ipamorelin appears to be a more biased agonist toward GH release specifically.
Dosing Patterns in Research Literature
Published research protocols have used the following ranges (note: these are research reference points, not dosing recommendations):
Ipamorelin: Preclinical studies have used 200–300 μg/kg in rats, with human-equivalent dose estimation ranging in human pharmacokinetic modeling studies. Human research is limited but phase II trials have used doses in the 200–300 μg range administered subcutaneously.
GHRP-6: Rat studies have used 100–300 μg/kg. Human studies have used doses from 1 μg/kg up to 2–3 μg/kg IV or SC, with the 1 μg/kg IV dose commonly used in GH stimulation testing research.
What the Research Says: Selected Studies
Ipamorelin — Key Findings
The landmark Raun et al. (1998) paper established ipamorelin's selectivity profile. Subsequent research has explored ipamorelin in the context of GH deficiency, postoperative ileus (a gastrointestinal research application where GHS-R activity in the gut is relevant), and sarcopenia models. Ipamorelin reached Phase II clinical trials for postoperative ileus — one of the few GHS peptides to advance that far.
GHRP-6 — Key Findings
GHRP-6 has an extensive preclinical literature. Beyond GH secretion, research has examined its cardioprotective properties (GHRP-6 has been studied in myocardial infarction models, where GHS-R activation appears to have cytoprotective effects independent of GH), its role in appetite regulation, and its interactions with the hypothalamic-pituitary-adrenal axis.
Practical Research Notes
Both peptides are lyophilized powders requiring reconstitution with bacteriostatic water before use in research Both are sensitive to heat and repeated freeze-thaw cycles — store reconstituted peptides refrigerated and avoid multiple freeze-thaw cycles Both have short half-lives in solution — reconstituted peptides should be used within typical research storage windows (2–4 weeks refrigerated) Pulsatile administration timing matters in research design — both peptides mimic natural pulsatile GH release, so administration timing relative to natural GH pulsatility should be considered in protocol design
Summary
Ipamorelin and GHRP-6 are both legitimate, well-studied GH secretagogues with distinct research niches. Ipamorelin is the cleaner, more selective tool — ideal for research that needs GH stimulation without confounding hormonal noise. GHRP-6 is more potent, engages the full ghrelin pathway, and is the right tool when appetite, GI, or broader GHS-R signaling is part of the research question.
Neither is universally "better." The right compound depends on what question you're asking.
Research-Grade Peptides, Third-Party Verified
Every peptide at NorthPeptide ships with a certificate of analysis. 99%+ purity guaranteed.
Browse All Peptides →
Summary of Key Research References
Citation Finding Study Type Raun K, et al. (1998). Eur J Endocrinol. PMC: PMID 9662588 Ipamorelin: selective GH release without cortisol/ACTH in rats Preclinical (rat) Bowers CY, et al. (1984). Endocrinology. PMID 6329898 GHRP-6 discovery: potent GH release via novel receptor pathway Preclinical Popovic V, et al. (1995). J Clin Endocrinol Metab. PMID 7608264 GHRP-6 stimulates GH, cortisol, and ACTH in humans Clinical (human) Bhatt DL, et al. (2011). J Am Coll Cardiol. PMID 20723842 GHS-R activation and cardioprotection — GHRP-6 in MI models Preclinical review Svensson J, et al. (2000). J Clin Endocrinol Metab. PMID 10902793 Ipamorelin dose-response: GH without prolactin or cortisol in humans Clinical (human) Kojima M, et al. (1999). Nature. PMID 10604470 Ghrelin discovery — endogenous GHS-R ligand explaining GHRP-6 mechanism Discovery paper Falutz J, et al. (2007). N Engl J Med. PMID 17942873 GH secretagogue research in body composition — ipamorelin class context Clinical trial
Disclaimer: This article is for educational and informational purposes only. Ipamorelin and GHRP-6 are research compounds intended for laboratory use only. They are not approved for human consumption by the FDA or any regulatory body. NorthPeptide does not provide medical advice. Always consult a licensed healthcare professional before considering any peptide-related research.